Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia

This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular lymphocytic leukemia (T-LGLL) requiring treatment, n=12. Patients will receive single agent golidocitinib at the previously established dose of 150 mg QD as determined in the phase I and II studies of golidocitinib.

NCT Number	NCT07682792
Lead Sponsor	Washington University School of Medicine Collaborators: Dizal Pharmaceuticals
Conditions	Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Enrollment	24 participants
Start Date	2026-09-30
Primary Completion	2030-01-31 (estimated)
Study Completion	2032-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-06